EasyDNNNews

Monday, September 23, 2019

'Dramatic' survival increase with CDK4/6 inhibitor, new settings for immunotherapy, PFS gain with AKT inhibitor

Medpage Today (9/23) reports that atients with advanced hormone receptor (HR)-positive breast cancer obtained a first-ever survival improvement with a targeted agent as ribociclib (Kisqali) plus endocrine therapy led to a 24% absolute improvement over endocrine therapy alone, according to research presented at the American Society of Clinical Oncology (ASCO) meeting.

Print
Author: Nicole Hardy
0 Comments

Theme picker